<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">genort</journal-id><journal-title-group><journal-title xml:lang="ru">Гений ортопедии</journal-title><trans-title-group xml:lang="en"><trans-title>Genij Ortopedii</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1028-4427</issn><issn pub-type="epub">2542-131X</issn><publisher><publisher-name>ЦЕНТР ИЛИЗАРОВА</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18019/1028-4427-2025-31-3-322-333</article-id><article-id custom-type="elpub" pub-id-type="custom">genort-3251</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original articles</subject></subj-group></article-categories><title-group><article-title>Особенности течения и среднесрочные исходы имплантат-ассоциированной инфекции, вызванной ведущими грамотрицательными возбудителями</article-title><trans-title-group xml:lang="en"><trans-title>Course and medium-term outcomes of implant-associated infection caused by leading gram-negative pathogens</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4891-4963</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Туфанова</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Tufanova</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ольга Сергеевна Туфанова — врач — клинический фармаколог</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Olga S. Tufanova — Clinical Pharmacologist</p><p>St. Petersburg</p></bio><email xlink:type="simple">katieva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2083-2424</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Божкова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bozhkova</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Светлана Анатольевна Божкова — доктор медицинских наук, заведующая отделением, профессор кафедры</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Svetlana A. Bozhkova — Doctor of Medical Sciences, Head of the Department, Professor of Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">clinpharm-rniito@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2326-7413</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гордина</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gordina</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Екатерина Михайловна Гордина — кандидат медицинских наук, старший научный сотрудник</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Ekaterina M. Gordina — Candidate of Medical Sciences, Senior Researcher</p><p>St. Petersburg</p></bio><email xlink:type="simple">emgordina@win.rniito.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5087-6081</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Артюх</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Artyukh</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Василий Алексеевич Артюх — доктор медицинских наук, заведующий отделением</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Vasily A. Artyukh — Doctor of Medical Sciences, Head of the Department</p><p>St. Petersburg</p></bio><email xlink:type="simple">artyukhva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр травматологии и ортопедии имени Р.Р. Вредена</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vreden National Medical Research Center of Traumatology and Orthopedics</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>28</day><month>06</month><year>2025</year></pub-date><volume>31</volume><issue>3</issue><fpage>322</fpage><lpage>333</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Туфанова О.С., Божкова С.А., Гордина Е.М., Артюх В.А., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Туфанова О.С., Божкова С.А., Гордина Е.М., Артюх В.А.</copyright-holder><copyright-holder xml:lang="en">Tufanova O.S., Bozhkova S.A., Gordina E.M., Artyukh V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ilizarov-journal.com/jour/article/view/3251">https://www.ilizarov-journal.com/jour/article/view/3251</self-uri><abstract><p>Введение. Имплантат-ассоциированная инфекция (ИАИ), вызванная грамотрицательными патогенами, характеризуется более тяжелым, рецидивирующим течением и более высокой летальностью. Основной причиной этого является рост антибиотикорезистентности данных возбудителей и сложность выбора препаратов для стационарного и амбулаторного этапов лечения.Цель работы — оценить влияние различных факторов и сравнить особенности течения имплантатассоциированной инфекции, вызванной ведущими Гр(–) возбудителями (P. aeruginosa, K. pneumoniae, A. baumannii), у пациентов с благоприятными и неблагоприятными исходами лечения.Материалы и методы. Выполнен ретроспективный анализ историй болезни 172 пациентов, пролеченных по поводу имплантат-ассоциированной инфекции, вызванной P. aeruginosa, K. pneumoniae, A. baumannii. По результатам телефонного анкетирования или осмотра пациенты согласно критериям Делфи разделены на две группы: с благоприятным (n = 95) и неблагоприятным (n = 77) исходом лечения. В программе IBM SPSS STATISTICS (версия 26) выполнен статистический анализ влияния на исходы лечения различных факторов анамнеза, лабораторного и микробиологического исследований, особенностей хирургического вмешательства, антибактериальной терапии и течения раннего послеоперационного периода.Результаты. Среди исследуемых пациентов доля неблагоприятных исходов составила 45 %, летальный исход — 10 %. При проведении сравнительного исследования показано статистически значимое влияние на развитие неблагоприятного исхода послеоперационного уровня сывороточного альбумина (p = 0,002), чувствительности выделенного изолята к тестируемым антибактериальным препаратам (p = 0,011), выделение возбудителя из биоматериала пациентов в послеоперационном периоде (p = 0,001), более частой потребности в назначении внутривенного альбумина и железа (p = 0,003 и p = 0,056 соответственно) и необходимости в проведении повторного хирургического вмешательствав раннем послеоперационном периоде (p = 0,001).Обсуждение. ИАИ, обусловленная грамотрицательными бактериями, характеризуется длительным рецидивирующим течением и высокой летальностью, что связано, прежде всего, с растущей антибиотикорезистентностью возбудителей и требует индивидуального подхода к хирургическому и медикаментозному лечению, а также разработки новых тактических подходов к терапии.Заключение. Гипоальбуминемия и антибактериальная резистентность выделенных изолятов P. aeruginosa, K. pneumoniae, A. baumannii, выделение возбудителя в послеоперационном материале, а также потребность в хирургическом вмешательстве в раннем послеоперационном периоде, являются факторами риска неблагоприятного исхода.</p></abstract><trans-abstract xml:lang="en"><p>Introduction Implant-associated infection (IAI) caused by gram-negative pathogens is characterized by a more severe, recurrent course and higher mortality than the one caused by gram-positive ones. The main reason is growing antibiotic resistance of these pathogens and the complexity of choosing drugs for inpatient and outpatient therapy.Purpose To evaluate the influence of various factors and compare the features of the course of implant-associated infection caused by P. aeruginosa, K. pneumoniae, A. baumannii in patients with positive and poor treatment outcomesMethods A retrospective analysis of the medical records of 172 patients treated at the Department of Purulent Osteology between January 1, 2017 and December 31, 2022 for implant-associated infection caused by  P. aeruginosa, K. pneumoniae, A. baumannii was conducted. Based on the results of a telephone survey or examination, patients were divided into 2 groups: positive and poor treatment outcomes by Delphi criteria. The impact of various factors in the anamnesis, laboratory and microbiological analysis, features of surgical intervention, antibacterial therapy and the course of the early postoperative period on the outcomes was analyzed in the IBM SPSS STATISTICS (version 26).Results Among patients with IAI caused by gram-negative bacteria, the rate of poor outcomes was 45 %, with fatality rate of 10 %. During the comparative study, a statistically significant effect on the development of  a  poor outcome was shown by the postoperative level of serum albumin (p = 0.002), the sensitivity of the isolated isolate to the tested antibacterial drugs (p = 0.011), the isolation of the pathogen from patients’ biomaterial in the postoperative period (p = 0.001), a more frequent need for intravenous administration of albumin and iron (p = 0.003 and p = 0.056, respectively) and the need for repeated surgical intervention in the early postoperative period (p = 0.001).Discussion IAI caused by gram-negative bacteria is characterized by a prolonged recurrent course and high mortality, primarily associated with the overall growing antibiotic resistance of pathogens which requires an individual approach to both surgical treatment and drug therapy, as well as the development of new tactical approaches to therapy.Conclusion The rate of poor outcomes was 45 %. Hypoalbuminemia and antibacterial resistance of isolates of P. aeruginosa, K. pneumoniae, A. baumannii, detection of the pathogens in the postoperative material, as well as the need for surgical reoperation in the early postoperative period, are risk factors for poor outcomes.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>имплантат-ассоциированная инфекция</kwd><kwd>перипротезная инфекция</kwd><kwd>имплантат-ассоциированный остеомиелит</kwd><kwd>энтеробактерии</kwd><kwd>K. pneumoniae</kwd><kwd>P. aeruginosa</kwd><kwd>A. baumannii</kwd><kwd>антибактериальная терапия</kwd><kwd>фторхинолоны</kwd><kwd>ко-тримоксазол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>implant-associated infection</kwd><kwd>periprosthetic joint infection</kwd><kwd>osteomyelitis</kwd><kwd>enterobacteria</kwd><kwd>K. pneumoniae</kwd><kwd>P. aeruginosa</kwd><kwd>A. baumannii</kwd><kwd>antibacterial therapy</kwd><kwd>fluoroquinolones</kwd><kwd>co-trimoxazole</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Singh JA, Yu S, Chen L, Cleveland JD. Rates of Total Joint Replacement in the United States: Future Projections to 2020-2040 Using the National Inpatient Sample. J Rheumatol. 2019;46(9):1134-1140. doi: 10.3899/jrheum.170990.</mixed-citation><mixed-citation xml:lang="en">Singh JA, Yu S, Chen L, Cleveland JD. Rates of Total Joint Replacement in the United States: Future Projections to 2020‑2040 Using the National Inpatient Sample. J Rheumatol. 2019;46(9):1134-1140. doi: 10.3899/jrheum.170990.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Tubb CC, Polkowksi GG, Krause B. Diagnosis and Prevention of Periprosthetic Joint Infections. J Am Acad Orthop Surg. 2020;28(8):e340-e348. doi: 10.5435/JAAOS-D-19-00405.</mixed-citation><mixed-citation xml:lang="en">Tubb CC, Polkowksi GG, Krause B. Diagnosis and Prevention of Periprosthetic Joint Infections. J Am Acad Orthop Surg. 2020;28(8):e340-e348. doi: 10.5435/JAAOS-D-19-00405.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Birt MC, Anderson DW, Bruce Toby E, Wang J. Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies. J Orthop. 2016;14(1):45-52. doi: 10.1016/j.jor.2016.10.004.</mixed-citation><mixed-citation xml:lang="en">Birt MC, Anderson DW, Bruce Toby E, Wang J. Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies. J Orthop. 2016;14(1):45-52. doi: 10.1016/j.jor.2016.10.004.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Liukkonen RJ, Honkanen M, Reito AP, et al. Trends in Revision Hip Arthroplasty for Prosthetic Joint Infection: A Single-Center Study of 423 Hips at a High-Volume Center Between 2008 and 2021. J Arthroplasty. 2023;38(6):1151-1159. doi: 10.1016/j.arth.2023.02.061.</mixed-citation><mixed-citation xml:lang="en">Liukkonen RJ, Honkanen M, Reito AP, et al. Trends in Revision Hip Arthroplasty for Prosthetic Joint Infection: A SingleCenter Study of 423 Hips at a High-Volume Center Between 2008 and 2021. J Arthroplasty. 2023;38(6):1151-1159. doi: 10.1016/j.arth.2023.02.061.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Касимова А.Р., Туфанова О.С., Гордина Е.М. и др. Двенадцатилетняя динамика спектра ведущих возбудителей ортопедической инфекции: ретроспективное исследование. Травматология и ортопедия России. 2024;30(1):66-75. doi: 10.17816/2311-2905-16720.</mixed-citation><mixed-citation xml:lang="en">Kasimova AR, Trufanova OS, Gordina EM, et al. Twelve-year dynamics of leading pathogens spectrum causing orthopedic infection: a retrospective study. Traumatology and Orthopedics of Russia. 2024;30(1):66-75. doi: 10.17816/2311-2905-16720.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bozhkova S, Tikhilov R, Labutin D, et al. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol. 2016;17(4):369-376. doi: 10.1007/s10195-016-0417-8.</mixed-citation><mixed-citation xml:lang="en">Bozhkova S, Tikhilov R, Labutin D, et al. Failure of the first step of two-stage revision due to polymicrobial prosthetic joint infection of the hip. J Orthop Traumatol. 2016;17(4):369-376. doi: 10.1007/s10195-016-0417-8.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tsikopoulos K, Meroni G. Periprosthetic Joint Infection Diagnosis: A Narrative Review. Antibiotics (Basel). 2023;12(10):1485. doi: 10.3390/antibiotics12101485.</mixed-citation><mixed-citation xml:lang="en">Tsikopoulos K, Meroni G. Periprosthetic Joint Infection Diagnosis: A Narrative Review. Antibiotics (Basel). 2023;12(10):1485. doi: 10.3390/antibiotics12101485.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pfang BG, García-Cañete J, García-Lasheras J, et al. Orthopedic Implant-Associated Infection by Multidrug Resistant Enterobacteriaceae. J Clin Med. 2019;8(2):220. doi: 10.3390/jcm8020220.</mixed-citation><mixed-citation xml:lang="en">Pfang BG, García-Cañete J, García-Lasheras J, et al. Orthopedic Implant-Associated Infection by Multidrug Resistant Enterobacteriaceae. J Clin Med. 2019;8(2):220. doi: 10.3390/jcm8020220.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty. 2011;26(6 Suppl):104-108. doi: 10.1016/j.arth.2011.03.044.</mixed-citation><mixed-citation xml:lang="en">Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J. Prosthetic joint infection caused by gramnegative organisms. J Arthroplasty. 2011;26(6 Suppl):104-108. doi: 10.1016/j.arth.2011.03.044.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Кочиш А.А., Божкова С.А. Современное cостояние проблемы лечения пациентов с рецидивирующим течением перипротезной инфекции тазобедренного сустава (обзор литературы). Кафедра травматологии и ортопедии. 2020;(3):11-22. doi: 10.17238/issn2226-2016.2020.3.11-22.</mixed-citation><mixed-citation xml:lang="en">Kochish AA, Bozhkova SA. Modern state of problem for treating patients with recurrent hip periprosthetic joint infection (Literature review). Department of traumatology and orthopedics. 2020;(3):11-22. (In Russ.) doi: 10.17238/issn2226-2016.2020.3.11-22.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med. 2020;382(14):1309-1319. doi: 10.1056/NEJMoa1914433.</mixed-citation><mixed-citation xml:lang="en">Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-Resistant Bacterial Infections in U.S. Hospitalized Patients, 2012-2017. N Engl J Med. 2020;382(14):1309-1319. doi: 10.1056/NEJMoa1914433.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez MR, Gonzalez J, Patel RV, et al. Microbiology, treatment, and postoperative outcomes of gram-negative prosthetic joint infections - a systematic review of the literature. J Am Acad Orthop Surg. 2024 Sep 5. doi: 10.5435/JAAOS-D-23-01203.</mixed-citation><mixed-citation xml:lang="en">Gonzalez MR, Gonzalez J, Patel RV, et al. Microbiology, treatment, and postoperative outcomes of gram-negative prosthetic joint infections - a systematic review of the literature. J Am Acad Orthop Surg. 2024 Sep 5. doi: 10.5435/JAAOS-D-23-01203.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fantoni M, Borrè S, Rostagno R, et al. Epidemiological and clinical features of prosthetic joint infections caused by gram-negative bacteria. Eur Rev Med Pharmacol Sci. 2019;23(2 Suppl):187-194. doi: 10.26355/eurrev_201904_17490.</mixed-citation><mixed-citation xml:lang="en">Fantoni M, Borrè S, Rostagno R, et al. Epidemiological and clinical features of prosthetic joint infections caused by gram-negative bacteria. Eur Rev Med Pharmacol Sci. 2019;23(2 Suppl):187-194. doi: 10.26355/eurrev_201904_17490.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Туфанова О.С., Касимова А.Р., Астахов Д.И. и др. Факторы, влияющие на течение и прогноз имплантат-ассоциированной инфекции, вызванной Klebsiella spp. Травматология и ортопедия России. 2024;30(2):40-53. doi: 10.17816/2311-2905-16719.</mixed-citation><mixed-citation xml:lang="en">Tufanova OS, Kasimova AR, Astakhov DI et al. Factors affecting the course and prognosis of Implant-associated Infection caused by Klebsiella spp. Traumatology and Orthopedics of Russia. 2024;30(2):40-53. doi: 10.17816/2311-2905-16719.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Papadopoulos A, Ribera A, Mavrogenis AF, et al. Multidrug-resistant and extensively drug-resistant Gram-negative prosthetic joint infections: Role of surgery and impact of colistin administration. Int J Antimicrob Agents. 2019;53(3):294-301. doi: 10.1016/j.ijantimicag.2018.10.018.</mixed-citation><mixed-citation xml:lang="en">Papadopoulos A, Ribera A, Mavrogenis AF, et al. Multidrug-resistant and extensively drug-resistant Gramnegative prosthetic joint infections: Role of surgery and impact of colistin administration. Int J Antimicrob Agents. 2019;53(3):294‑301. doi: 10.1016/j.ijantimicag.2018.10.018.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res. 2013;471(7):2374-2382. doi: 10.1007/s11999-013-2866-1.</mixed-citation><mixed-citation xml:lang="en">Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res. 2013;471(7):2374-2382. doi: 10.1007/s11999-013‑2866-1.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Abukhalil AD, Barakat SA, Mansour A, et al. ESKAPE Pathogens: antimicrobial resistance patterns, risk factors, and outcomes a retrospective cross-sectional study of hospitalized patients in Palestine. Infect Drug Resist. 2024;17:3813-3823. doi: 10.2147/IDR.S471645.</mixed-citation><mixed-citation xml:lang="en">Abukhalil AD, Barakat SA, Mansour A, et al. ESKAPE Pathogens: antimicrobial resistance patterns, risk factors, and outcomes a retrospective cross-sectional study of hospitalized patients in Palestine. Infect Drug Resist. 2024;17:3813-3823. doi: 10.2147/IDR.S471645.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Venkateswaran P, Vasudevan S, David H, et al. Revisiting ESKAPE Pathogens: virulence, resistance, and combating strategies focusing on quorum sensing. Front Cell Infect Microbiol. 2023;13:1159798. doi: 10.3389/fcimb.2023.1159798.</mixed-citation><mixed-citation xml:lang="en">Venkateswaran P, Vasudevan S, David H, et al. Revisiting ESKAPE Pathogens: virulence, resistance, and combating strategies focusing on quorum sensing. Front Cell Infect Microbiol. 2023;13:1159798. doi: 10.3389/fcimb.2023.1159798.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Adar A, Zayyad H, Azrad M, et al. Clinical and demographic characteristics of patients with a new diagnosis of carriage or clinical infection with carbapenemase-producing Enterobacterales: a retrospective study. Front Public Health. 2021;9:616793. doi: 10.3389/fpubh.2021.616793.</mixed-citation><mixed-citation xml:lang="en">Adar A, Zayyad H, Azrad M, et al. Clinical and demographic characteristics of patients with a new diagnosis of carriage or clinical infection with carbapenemase-producing Enterobacterales: a retrospective study. Front Public Health. 2021;9:616793. doi: 10.3389/fpubh.2021.616793.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lasko MJ, Nicolau DP. Carbapenem-resistant Enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Curr Infect Dis Rep. 2020;22(3):6. doi: 10.1007/s11908-020-0716-3.</mixed-citation><mixed-citation xml:lang="en">Lasko MJ, Nicolau DP. Carbapenem-resistant Enterobacterales: considerations for treatment in the era of new antimicrobials and evolving enzymology. Curr Infect Dis Rep. 2020;22(3):6. doi: 10.1007/s11908-020-0716-3.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">ohnson A, McEntee L, Farrington N, et al. Pharmacodynamics of cefepime combined with the novel extended-spectrum-β-Lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e00180-20. doi: 10.1128/AAC.00180-20.</mixed-citation><mixed-citation xml:lang="en">ohnson A, McEntee L, Farrington N, et al. Pharmacodynamics of cefepime combined with the novel extendedspectrum-β-Lactamase (ESBL) inhibitor enmetazobactam for murine pneumonia caused by ESBL-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(6):e00180-20. doi: 10.1128/AAC.00180-20.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi: 10.3389/fmicb.2019.00080.</mixed-citation><mixed-citation xml:lang="en">Sheu CC, Chang YT, Lin SY, et al. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi: 10.3389/fmicb.2019.00080.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Wimmer MD, Hischebeth GTR, Randau TM, et al. Difficult-to-treat pathogens significantly reduce infection resolution in periprosthetic joint infections. Diagn Microbiol Infect Dis. 2020;98(2):115114. doi: 10.1016/j.diagmicrobio.2020.115114.</mixed-citation><mixed-citation xml:lang="en">Wimmer MD, Hischebeth GTR, Randau TM, et al. Difficult-to-treat pathogens significantly reduce infection resolution in periprosthetic joint infections. Diagn Microbiol Infect Dis. 2020;98(2):115114. doi: 10.1016/j.diagmicrobio.2020.115114.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Kalbian IL, Goswami K, Tan TL, et al. Treatment outcomes and attrition in gram-negative periprosthetic joint infection. J Arthroplasty. 2020;35(3):849-854. doi: 10.1016/j.arth.2019.09.044.</mixed-citation><mixed-citation xml:lang="en">Kalbian IL, Goswami K, Tan TL, et al. Treatment outcomes and attrition in gram-negative periprosthetic joint infection. J Arthroplasty. 2020;35(3):849-854. doi: 10.1016/j.arth.2019.09.044.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Артюх В.А., Божкова С.А., Тихилов Р.М. и др. Факторы риска летального исхода после хирургического лечения больных хронической перипротезной инфекцией тазобедренного сустава. Гений Ортопедии. 2021;27(5):555-561. doi: 10.18019/1028-4427-2021-27-5-555-561.</mixed-citation><mixed-citation xml:lang="en">Artyukh VA, Bozhkova SA, Tikhilov RM, et al. Risk factors for lethal outcomes after surgical treatment of patients with chronic periprosthetic hip joint infection. Genij Ortopedii. 2021;27(5):555-561. doi: 10.18019/1028-4427-2021-27-5-555-561.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Grossi O, Asseray N, Bourigault C, et al. Gram-negative prosthetic joint infections managed according to a multidisciplinary standardized approach: risk factors for failure and outcome with and without fluoroquinolones. J Antimicrob Chemother. 2016;71(9):2593-2597. doi: 10.1093/jac/dkw202.</mixed-citation><mixed-citation xml:lang="en">Grossi O, Asseray N, Bourigault C, et al. Gram-negative prosthetic joint infections managed according to a multidisciplinary standardized approach: risk factors for failure and outcome with and without fluoroquinolones. J Antimicrob Chemother. 2016;71(9):2593-2597. doi: 10.1093/jac/dkw202.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hsieh PH, Lee MS, Hsu KY, et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009;49(7):1036-1043. doi: 10.1086/605593.</mixed-citation><mixed-citation xml:lang="en">Hsieh PH, Lee MS, Hsu KY, et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis. 2009;49(7):1036-1043. doi: 10.1086/605593.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Scarcella NR, Mills FB, Seidelman JL, Jiranek WA. The effect of nutritional status in the treatment of periprosthetic joint infections in total hip arthroplasty. J Arthroplasty. 2024;39(9S1):S225-S228. doi: 10.1016/j.arth.2024.06.040.</mixed-citation><mixed-citation xml:lang="en">Scarcella NR, Mills FB, Seidelman JL, Jiranek WA. The effect of nutritional status in the treatment of periprosthetic joint infections in total hip arthroplasty. J Arthroplasty. 2024;39(9S1):S225-S228. doi: 10.1016/j.arth.2024.06.040.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99-110. doi: 10.2165/11539220-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99-110. doi: 10.2165/11539220-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Bohl DD, Shen MR, Kayupov E, et al. Is hypoalbuminemia associated with septic failure and acute infection after revision total joint arthroplasty? A study of 4517 patients from the national surgical quality improvement program. J Arthroplasty. 2016;31(5):963-967. doi: 10.1016/j.arth.2015.11.025.</mixed-citation><mixed-citation xml:lang="en">Bohl DD, Shen MR, Kayupov E, et al. Is hypoalbuminemia associated with septic failure and acute infection after revision total joint arthroplasty? A study of 4517 patients from the national surgical quality improvement program. J Arthroplasty. 2016;31(5):963-967. doi: 10.1016/j.arth.2015.11.025.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Божкова С.А., Ливенцов В.Н., Тихилов Р.М. и др. Белково-энергетическая недостаточность как предиктор ранних повторных ревизий после санирующих операций у пациентов с трудноизлечимой перипротезной инфекцией. Травматология и ортопедия России. 2022;28(1):39-45. doi: 10.17816/2311-2905-1717.</mixed-citation><mixed-citation xml:lang="en">Bozhkova SA, Liventsov VN, Tikhilov RM, et al. Protein-energy malnutrition as a predictor of early recurrent revisions after debridement surgery in patients with difficult-to-treat periprosthetic infection. Traumatology and Orthopedics of Russia. 2022;28(1):39-45. doi: 10.17816/2311-2905-1717.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Swenson RD, Butterfield JA, Irwin TJ, et al. Preoperative anemia is associated with failure of open debridement polyethylene exchange in acute and acute hematogenous prosthetic joint infection. J Arthroplasty. 2018;33(6):1855-1860. doi: 10.1016/j.arth.2018.01.042.</mixed-citation><mixed-citation xml:lang="en">Swenson RD, Butterfield JA, Irwin TJ, et al. Preoperative anemia is associated with failure of open debridement polyethylene exchange in acute and acute hematogenous prosthetic joint infection. J Arthroplasty. 2018;33(6):1855-1860. doi: 10.1016/j.arth.2018.01.042.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Винклер Т., Трампуш А., Ренц Н. и др. Классификация и алгоритм диагностики и лечения перипротезной инфекции тазобедренного сустава. Травматология и ортопедия России. 2016;22(1):33-45. doi: 10.21823/2311-2905-2016-0-1-33-45.</mixed-citation><mixed-citation xml:lang="en">Winkler T, Trumpuz A, Renz N, et al. Classification and algorithm for diagnosis and treatment of hip periprosthetic infection. Traumatology and orthopedics of Russia. 2016;22(1):33-45. (In Russ.) doi: 10.21823/2311-2905-2016-0‑1‑33‑45.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med. 2021;384(21):1991-2001. doi: 10.1056/NEJMoa2020198.</mixed-citation><mixed-citation xml:lang="en">Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic therapy for 6 or 12 weeks for prosthetic joint infection. N Engl J Med. 2021;384(21):1991-2001. doi: 10.1056/NEJMoa2020198.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Azamgarhi T, Scarborough M, Peter-Akhigbe V, et al. Fluoroquinolones in orthopaedic infection: balancing risks and rewards. J Antimicrob Chemother. 2024;79(10):2413-2416. doi: 10.1093/jac/dkae286.</mixed-citation><mixed-citation xml:lang="en">Azamgarhi T, Scarborough M, Peter-Akhigbe V, et al. Fluoroquinolones in orthopaedic infection: balancing risks and rewards. J Antimicrob Chemother. 2024;79(10):2413-2416. doi: 10.1093/jac/dkae286.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Rodríguez-Pardo D, Pigrau C, Lora-Tamayo J, et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect. 2014;20(11):O911-O919. doi: 10.1111/1469-0691.12649.</mixed-citation><mixed-citation xml:lang="en">Rodríguez-Pardo D, Pigrau C, Lora-Tamayo J, et al. Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect. 2014;20(11):O911-O919. doi: 10.1111/1469-0691.12649.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Цискарашвили АВ, Меликова РЭ, Новожилова ЕА. Анализ шестилетнего мониторинга основных возбудителей перипротезной инфекции крупных суставов и их тенденция к резистентности. Гений Ортопедии. 2022;28(2):179-188. doi: 10.18019/1028-4427-2022-28-2-179-188.</mixed-citation><mixed-citation xml:lang="en">Tsiskarashvili AV, Melikova RE, Novozhilova EA. Analysis of six-year monitoring of common pathogens causing periprosthetic joint infection of major joints and the tendency to resistance. Genij Ortopedii. 2022;28(2):179-188. doi: 10.18019/1028-4427-2022-28-2-179-188.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepimefluoroquinolone combination. Clin Microbiol Infect. 2006;12(10):1030-1033. doi: 10.1111/j.1469-0691.2006.01523.x.</mixed-citation><mixed-citation xml:lang="en">Legout L, Senneville E, Stern R, et al. Treatment of bone and joint infections caused by Gram-negative bacilli with a cefepime-fluoroquinolone combination. Clin Microbiol Infect. 2006;12(10):1030-1033. doi: 10.1111/j.1469-0691.2006.01523.x.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019;81:128-136. doi: 10.1016/j.ijid.2019.02.005.</mixed-citation><mixed-citation xml:lang="en">Thabit AK, Fatani DF, Bamakhrama MS, et al. Antibiotic penetration into bone and joints: An updated review. Int J Infect Dis. 2019;81:128-136. doi: 10.1016/j.ijid.2019.02.005.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Божкова С.А., Касимова А.Р., Тихилов Р.М. и др. Неблагоприятные тенденции в этиологии ортопедической инфекции: результаты 6-летнего мониторинга структуры и резистентности ведущих возбудителей. Травматология и ортопедия России. 2018;24(4):20-31. doi: 10.21823/2311-2905-2018-24-4-20-31.</mixed-citation><mixed-citation xml:lang="en">Bozhkova SA, Kasimova AR, Tikhilov RM, et al. Adverse trends in the etiology of orthopedic Infection: results of 6-year monitoring of the structure and resistance of leading Pathogens. Traumatology and orthopedics of Russia. 2018;24(4):20‑31. doi: 10.21823/2311-2905-2018-24-4-20-31.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Cisse H, Vernet-Garnier V, Hentzien M, et al. Treatment of bone and joint infections caused by Enterobacter cloacae with a fluoroquinolone-cotrimoxazole combination. Int J Antimicrob Agents. 2019;54(2):245-248. doi: 10.1016/j.ijantimicag.2019.05.010.</mixed-citation><mixed-citation xml:lang="en">Cisse H, Vernet-Garnier V, Hentzien M, et al. Treatment of bone and joint infections caused by Enterobacter cloacae with a fluoroquinolone-cotrimoxazole combination. Int J Antimicrob Agents. 2019;54(2):245-248. doi: 10.1016/j. ijantimicag.2019.05.010.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
